Jul 26, 2022

SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial

Posted by in category: biotech/medical

Additional outpatient therapies which are readily accessible will be essential to reduce COVID-19 illness progression in high risk individuals. Especially as the virus continues to mutate with greater transmissibility despite increased global vaccination.

Use of NONS in patients recently infected with SARS-CoV-2 accelerates nasal virus clearance.

Funding provided by Glenmark Pharmaceuticals Limited. Study medication provided by SaNOtize.

Leave a reply